Revisiting IBS: Recrafting the Diagnosis for More Timely Treatment and Patient-Centered Care


William D. Chey, MD, AGAF, FACG, FACP
Timothy T. Nostrant Collegiate Professor of Gastroenterology
Chief, Division of Gastroenterology & Hepatology and Professor of Nutrition Sciences
Departments of Internal Medicine and Nutritional Sciences, Michigan Medicine, University of Michigan, Ann Arbor, MI
William D. Chey, MD, AGAF, FACG, FACP

Dr. Chey received a medical degree and training in internal medicine at Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained as faculty at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He holds a joint appointment in the Department of Nutrition Sciences.

Dr. Chey’s research interests focus on the diagnosis and treatment of functional bowel disorders and H. pylori infection. He has mentored more than 50 students, residents, fellows, and junior faculty, many of which are leaders in gastroenterology. He is a medical innovator and holds several patents. Dr. Chey is former Co-Editor-in-Chief of the American Journal of Gastroenterology and has authored more than 350 manuscripts, reviews, chapters, and books. He is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, Council of the American Neurogastroenterology and Motility Society, and Board of Directors of the International Foundation of Functional Gastrointestinal Disorders.

Dr. Chey has been elected to “Best Doctors” since 2001 and received the Dean’s Outstanding Clinician Award and Dean’s Award for Innovation and Commercialization at the University of Michigan. He has also received the Distinguished Clinician Award from the American Gastroenterological Association. In 2020 he was awarded honorary membership to the Academy of Nutrition and Dietetics and the prestigious Berk/Fise Award from the American College of Gastroenterology.

Lin Chang, MD
Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
Vice-Chief, Vatche and Tamar Manoukian Division of Digestive Diseases
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
Lin Chang, MD

Dr. Chang is a Professor of Medicine and Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine at the David Geffen School of Medicine at UCLA. She serves as the Co-Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA. She is also Program Director of the UCLA Gastroenterology Fellowship Program. Dr. Chang’s clinical expertise is in disorders of gut-brain interaction (also known as functional gastrointestinal disorders). Her research focuses on brain-gut interactions underlying irritable bowel syndrome (IBS), specifically, the pathophysiology of IBS related to stress, early life adversity, sex differences, genetic and epigenetic factors, and gut microbiome as well as the treatment of IBS. She has recently served as the Clinical Research Councillor of the AGA Governing Board. Dr. Chang previously served as President of the American Neurogastroenterology and Motility Society (ANMS) and is a member of the Rome Foundation Board of Directors.

Amy Ladewski, PA-C, RD, MMS
Physician Assistant, Digestive Health Center, Northwestern Memorial Hospital, Chicago, IL
Amy Ladewski, PA-C, RD, MMS

Amy Ladewski is a physician assistant within the department of digestive health at Northwestern Memorial Hospital in Chicago, IL. She specializes in functional bowel and neurogastromotility disorders, in addition to managing general GI patients. She currently serves as the Vice President of the national non-profit organization GHAPP (Gastroenterology & Hepatology Advanced Practice Providers), with a mission to educate and help advance the careers of GI APPs. Amy serves as an adjunct teacher for the Northwestern Feinberg School of Medicine Physician Assistance program and was recently awarded preceptor of the year. With a background as a registered dietitian, she prioritizes nutrition counseling with her patients. Amy strives to develop collaborative and trusted relationships with her patients to empower them toward better health and wellness.

Statement of Need

Despite being one of the most commonly encountered conditions in primary care and gastroenterology practices, an overwhelming number of patients with irritable bowel syndrome (IBS) remain undiagnosed. Misdiagnosis, misunderstanding, and a lack of patient-centered care alienate patients with IBS who are seeking support, guidance, and treatment. Newly published American College of Gastroenterology guidelines for diagnosing and treating patients with IBS exist but are not routinely implemented, resulting in diagnostic delays. There is a need for strategies to improve diagnostic accuracy, familiarization with efficacious and safe IBS therapies, and patient-centered care, including shared decision-making (SDM), education, and patient-reported outcomes (PROs).

This live CME Outfitters symposium will feature an expert panel discussion crafted with a focus on patients with IBS that provides strategies for obtaining accurate diagnosis, presents new and emerging clinical data on the efficacy and safety of IBS therapies, and details approaches for patient-centered care to achieve optimal outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Implement strategies to improve diagnostic accuracy of IBS through the use of patient queries and diagnostic tools.
  • Recognize efficacy and safety of IBS therapies to inform treatment decision-making.
  • Implement approaches for patient-centered care for IBS, such as SDM, education, and PROs.

Financial Support

Supported by educational grants from AbbVie Inc. and Ironwood Pharmaceuticals, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.5

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-22-073-H01-P

Nurses (ANCC) 1.5

This activity is designated for 1.5 contact hours. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

PAs (AAPA) 1.50

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chey reports the following financial relationships: Consultant: AbbVie Inc; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Covita; Everlywell, Inc.; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; ISOThrive Inc.; Nestle; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; Urovant Sciences, Inc.; and Vibrant Pharma Inc. Research Support: Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; U.S. Food and Drug Administration (FDA); National Institutes of Health (NIH); QOL Medical; and Salix Pharmaceuticals. Stock Shareholder (directly purchased): Options: Options: GI OnDEMAND; ISOThrive Inc.; and ModifyHealth, LLC. Other: Patents: Digital Manometry; Nutrition Health; and Rectal Expulsion Device

Dr. Chang reports the following financial relationships: Advisory Board: Ardelyx; Arena Pharmaceuticals, Inc.; Cosmo Pharmaceuticals; Immunic Therapeutics; Ironwood Pharmaceuticals, Inc.; Mauna Kea Technologies; and Protagonist Therapeutics Inc. Consultant: Trellus, Inc. Research Support: AnX Robotica; Arena Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; and Vanda Pharmaceuticals. Speakers Bureau: AbbVie Inc. Stock Shareholder (ownership interest): ModifyHealth, LLC and Trellus, Inc.

Ms. Ladewski reports the following financial relationships: Advisory Board: Mahana Therapeutics, Inc. and Phathom Pharmaceuticals. Consultant: Ironwood Pharmaceuticals, Inc. and Salix Pharmaceuticals. Speakers Bureau: Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc.

The following peer reviewer and CME Outfitters staff report no financial relationships:

  • Jeffrey Helfand, DO (peer reviewer)
  • Susan Perry (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-073-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Revisiting IBS: Recrafting the Diagnosis for More Timely Treatment and Patient-Centered Care
Event Date: 06/09/2022